Blood and Marrow Transplantation Long Term Management. Группа авторов

and GVHD PROs as predictors of HCT survival Conclusion References CHAPTER 45: Caregivers of long‐term survivors Introduction Frequency/cumulative incidence Risk factors Surveillance/ screening Recommendation for the survivors/caregivers/general practitioner References CHAPTER 46: Patient’s perspective Lilian Living a normal Life Hello Cancer So, here we go! Staging the Cancer Staging and Sarah Cannon Clinical Trials Lymphomaniac Remission PET Scan and What's Next? Vanderbilt Hematology and Stem Cell Clinic Transplant Day Now for the Fun Part: Four Months of Treatment Going Home Returning to Everyday Life Twenty‐Three and Me / Ancestory.Com Medical Surprises and Life for the past 10 Years Blood Clots More Post‐Transplant Medical Surprises Colonoscopy Colon Cancer Surgery Tumor Board Wake Up Call Radiation Treatments The Puppy from Hell The Move to Florida The last of the Cancer‐Related Episodes The Continuation of the Story but not the End So Much to be Thankful For

      10  APPENDIX 1: Commonly used transplant‐related medications in long‐term survivors References

      11  APPENDIX 2: The eGVHD App References

      12  Index

      13  End User License Agreement

      List of Tables

      1 Chapter 2Table 2.1 Transplant Registries Collecting Data on HCT Survivors

      2 Chapter 3Table 3.1 Different models of long‐term transplant clinicsTable 3.2 Significant aspects to consider when building up a long‐term follow...

      3 Chapter 4Table 4.1 Telehealth modalities that can apply to Long Term Follow Up (LTFU) ...Table 4.2 Safeguarding medical information and photos in telehealthTable 4.3 Benefits and challenges of the telemedicine LTFU model for HCT surv...

      4 Chapter 5Table 5.1 Elements of a survivorship care plan for patients treated with hema...Table 5.2 Check‐list of recommendations for counseling of the long‐term survi...Table 5.3 Summary of recommendations for screening and prevention of late com...

      5 Chapter 6Table 6.1 Non‐relapse late and very late effects after allogeneic HCT

      6 Chapter 7Table 7.1 Common Late Effects and Complications after Autologous Hematopoieti...

      7 Chapter 8Table 8.1 LTFU recommendations for survivors

      8 Chapter 10Table 10.1 Summary recommendations for screening and prevention of late compl...Table 10.2 Screening recommendations for subsequent malignancies in survivors...

      9 Chapter 13Table 13.1 Preventive options of infections in long‐term survivors after allo...Table 13.2 Preventive options of infections in long‐term survivors after auto...

      10 Chapter 14Table 14.1 Risk factors for progression to lower respiratory tract diseaseTable 14.2 Infection Control measures to reduce risk of CRV infection

      11 Chapter 15Table 15.1 Classification of patient/donor depending on the HBV markersTable 15.2 Recommended measures in HCT with patients/donors with HBV infectio...Table 15.3 Possible results of the HCV screening before HCTTable 15.4 Recommended AVT against HCV depending on the viral genotypeTable 15.5 Recommended measures in HCT when patient or donor are infected by ...Table 15.6 More frequently used antiviral drugs and combinationsTable 15.7 Effect of anti‐HIV agents on HSCT drugs metabolization

      12 Chapter 16Table 16.1 Approaches proposed to identify associated predictive biomarkers o...Table 16.2 Specific criteria for cGVHD from the 2014 Pathology